Research in the Dick Lab
TB and NTM drug discovery
The lab focuses on the discovery of new antibiotics for the treatment of TB and lung disease caused by Non-Tuberculous Mycobacteria (NTM). Building on this expertise, the group recently expanded its activities to include ESKAPE pathogens, opportunistically testing lead compounds against these high-priority multidrug-resistant organisms. At CDI-HMH, the team, co-led by Veronique Dartois, established a fully enabled drug discovery platform for the delivery of preclinical development candidates. In collaboration with medicinal chemistry partners and CROs, the group developed an attractive portfolio of reengineering and de novo discovery and development projects, complemented by repurposing studies.
Recent IF ≥ 10 Publications
Dartois, V., Lan, T., Ganapathy, U.S., Wong, C.F., Sarathy, J.P., Jimenez, D.C., Alshiraihi, I.M., Lam, H., Rodriguez, S., Xie, M., Soto-Ojeda, M., Jackson, M., Wheat, W., Dillman, N.C., Kostenkova, K., Schmitt, J., Mann, L., Richter, A., Imming, P., Sarathy, J., Kaya, F., Paruchuri, S., Tatek, B., Folvar, C., Proietto, J., Zimmerman, M., Gonzalez-Juarrero, M., Aldrich, C.C., Dick, T. (2025) Next-generation rifamycins for the treatment of mycobacterial infections. Proc Natl Acad Sci U S A. 122(18):e2423842122.
Dartois, V., & Dick, T. (2024). Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. Nat Rev Drug Discov. 23(5), 381–403.
Dartois, V., & Dick, T. (2024). Toward better cures for Mycobacterium abscessus lung disease. Clin Microbiol Rev. 37(4), e0008023.
Aragaw, W.W., Lee, B.M., Yang, X., Zimmerman, M.D., Gengenbacher, M., Dartois, V., Chui, W.K., Jackson, C.J., & Dick, T. (2021). Potency boost of a Mycobacterium tuberculosis dihydrofolate reductase inhibitor by multienzyme F420H2-dependent reduction. Proc Natl Acad Sci U S A. 118(25), e2025172118.
Gopal, P., Sarathy, J.P., Yee, M., Ragunathan, P., Shin, J., Bhushan, S., Zhu, J., Akopian, T., Kandror, O., Lim, T.K., Gengenbacher, M., Lin, Q., Rubin, E.J., Grüber, G., Dick, T. (2020) Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nat Commun. 11(1):1661.